A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy

被引:37
作者
Weber, J
Rangel, HR
Chakraborty, B
Tadele, M
Martinez, MA
Martinez-Picado, J
Marotta, ML
Mirza, M
Ruiz, L
Clotet, B
Wrin, T
Petropoulos, CJ
Quiñones-Mateu, ME
机构
[1] ViroLog Inc, San Francisco, CA USA
[2] Cleveland Clin Fdn, Lerner Res Inst, Dept Virol, Cleveland, OH 44195 USA
[3] Univ Badalona, Hosp Germans Trias & Pujol, Fundacio IrsiCaixa, Lab Retrovirol, Badalona, Spain
关键词
D O I
10.1099/vir.0.19123-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Despite numerous studies on human immunodeficiency virus type 1 (HIV-1) fitness, many key conceptual and technical questions are still unsolved. For example, the proper system to determine virus fitness of HIV-1 is still unknown. In this study, an assay was developed to estimate HIV-1 fitness based on growth competition experiments and TaqMan real-time PCR. This novel technique was compared with several methods (i.e. virus growth kinetics, growth competition/heteroduplex-tracking analysis and single-cycle replication capacity assay) in order to analyse the impact of various genomic regions and overall genetic background on virus fitness. HIV-1 primary isolates and three different sets of recombinant viruses [i.e. recombinant clones carrying protease (PR), reverse transcriptase (RT) or the 3' end of Gag, PR and RT (3'Gag/PR/RT), sequences amplified by PCR from the same primary isolates)] were evaluated. Here, it is demonstrated that, in spite of intrinsic differences, both growth competition/TaqMan and single-cycle replication assays detected a significant reduction in HIV-1 fitness as a consequence of drug-resistant mutations in pol. However, this new assay, based on HIV-1 isolates, may be useful to quantify replicative fitness in viruses from patients treated simultaneously with antiretroviral drugs targeting different genomic regions of HIV-1 (e.g. pol and env).
引用
收藏
页码:2217 / 2228
页数:12
相关论文
共 49 条
[1]   Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C [J].
Ball, SC ;
Abraha, A ;
Collins, KR ;
Marozsan, AJ ;
Baird, H ;
Quiñones-Mateu, ME ;
Penn-Nicholson, A ;
Murray, M ;
Richard, N ;
Lobritz, M ;
Zimmerman, PA ;
Kawamura, T ;
Blauvelt, A ;
Arts, EJ .
JOURNAL OF VIROLOGY, 2003, 77 (02) :1021-1038
[2]   Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults [J].
Barbour, JD ;
Wrin, T ;
Grant, RM ;
Martin, JN ;
Segal, MR ;
Petropoulos, CJ ;
Deeks, SG .
JOURNAL OF VIROLOGY, 2002, 76 (21) :11104-11112
[3]   HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness [J].
Berkhout, B .
JOURNAL OF BIOMEDICAL SCIENCE, 1999, 6 (05) :298-305
[4]   Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1 [J].
Bleiber, G ;
Munoz, M ;
Ciuffi, A ;
Meylan, P ;
Telenti, A .
JOURNAL OF VIROLOGY, 2001, 75 (07) :3291-3300
[5]   Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection [J].
Brenner, BG ;
Routy, JP ;
Petrella, M ;
Moisi, D ;
Oliveira, M ;
Detorio, M ;
Spira, B ;
Essabag, V ;
Conway, B ;
Lalonde, R ;
Sekaly, RP ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 2002, 76 (04) :1753-1761
[6]  
Cabana M, 1999, J MED VIROL, V59, P480, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt
[7]  
480::AID-JMV10&gt
[8]  
3.0.CO
[9]  
2-8
[10]  
Clavel F, 2000, Adv Pharmacol, V49, P41